

PubMed

Search: jak2 v617f

U.S. National Library of Medicine
National Institutes of Health

Filter your results: All (564)

[Manage Filters](#)

Display Settings: Summary, 20 per page, Sorted by Recently Added

Results: 561 to 564 of 564

561. JAK2 in myeloproliferative disorders is not just another kinase.
Tefferi A, Gilliland DG.
Cell Cycle. 2005 Aug;4(8):1053-6. Epub 2005 Aug 26.
PMID: 15970705 [PubMed - indexed for MEDLINE]
[Free article](#)
562. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC.
Blood. 2005 Sep 15;106(6):2162-8. Epub 2005 May 26.
PMID: 15920007 [PubMed - indexed for MEDLINE]
[Free article](#)
563. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A.
Blood. 2005 Aug 15;106(4):1207-9. Epub 2005 Apr 28.
PMID: 15860081 [PubMed - indexed for MEDLINE]
[Free article](#)
564. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC.
N Engl J Med. 2005 Apr 28;352(17):1779-90.
PMID: 15856187 [PubMed - indexed for MEDLINE]
[Free article](#)